Patch Test Results With Additions to the European Baseline Series, 2021/22—Joint European Results of the ESSCAA and the EBSB Working Groups of the ESCD, and the GEIDACC

Uter W, Wilkinson SM, Bauer A, Borrego L, Brans R, Buhl T, Dickel H, Gallo R, Arnau AG, Gonçalo M, Koumaki D, Navarini AA, Patruno C, Pónyai G, Rustemeyer T, Spiewak R, Stingeni L, Valiukevičienė S, Schuttelaar ML, Aerts O, Kränke B, Dendooven E, Simon D, Spring P, Beiteke U, Dietrich C, Schliemann S, Becker D, John SM, Wagner N, Weisshaar E, Gregoriou S, Napolitano M, Cousen P, Johnston GA, Salvador JFS, Carrillo JMC, Campos MM, Baldrich ES, Melé-Ninot G, Torrella CB, Pesqué D, Arnau AMG, Nieto MAP, Triviño FN, Borrego L, Gonzales IR, de la Fuente EG, Guijarro SC, de Frutos FJO, Romero FT, Sánchez TS, Manso PC, Barasoain MA, González ME, Gilo AS, Guillén PSP, Mercader-García P, Suárez CP, Ortega MEG, Rodríguez JJP, Miquel JM, Serna MR, Ninet VZ, Pérez RG (2026)

Publication Type: Journal article

Publication year: 2026

Journal

DOI: 10.1111/cod.70183

Abstract

Background: Allergens are periodically added to the European Baseline Series (EBS) to audit their value in consecutive patch testing. Objectives: To present results of audit allergens tested in consecutive patients in 54 departments in 13 European countries during 2021 and 2022. Methods: Anonymized or pseudonymized individual data, and partly aggregated data on patch test rest results and their clinical relevance were prospectively collected and centrally pooled and analyzed. Results: In 2021 and 2022, 18 832 patients were patch tested with the EBS, and 2860 with the TRUE Test baseline series (supplemented with some missing EBS allergens). Of these patients, 17 359 were additionally tested with one or more of the 19 audit allergen preparations examined. Apart from the terpene hydroperoxides (OOH) which yielded the highest numbers of positive patch test reactions (linalool-OOH 1% pet.: 7.65 (7.09%–8.23%) [95% CI] and limonene-OOH 0.3% pet. 6.78 (6.26%–7.32%)), positive reactions were most often seen to benzisothiazolinone (3.71 (3.3%–4.15%)), sodium metabisulfite (3.49 (3.14%–3.88%)), Evernia furfuracea (tree moss, 1.79 (1.4%–2.26%)), and decyl and lauryl glucoside, at 1.49 (1.25%–1.76%) and 1.26 (1.05%–1.51%), respectively. The other allergens yielded around 1% or fewer positive patch test reactions. Clinical relevance varied, with Evernia furfuracea, 2-bromo-2-nitropropane-1,3-diol and terpene hydroperoxides considered relevant in more than 2/3 cases, while for other frequent sensitizers benzisothiazolinone and sodium metabisulfite, relevance could be confirmed in half of the cases or less often. Conclusions: The current results, along with other published data, will serve to inform decisions concerning possible revision of the EBS, considering frequency of positive reactions, their clinical relevance and the overall reaction profile of each of the allergens.

Authors with CRIS profile

Involved external institutions

Leeds Teaching Hospitals NHS Trust United Kingdom (GB) University General Hospital of Heraklion Greece (GR) Universitätsspital Basel Switzerland (CH) University of Molise / Università degli Studi del Molise Italy (IT) Universität Osnabrück Germany (DE) Universitätsklinikum Göttingen Germany (DE) Semmelweis University / Semmelweis Egyetem Hungary (HU) Amsterdam University Medical Centers (Amsterdam UMC) / Amsterdam Universitair Medische Centra Netherlands (NL) Jagiellonian University / Uniwersytet Jagielloński (UJ) Poland (PL) Università degli Studi di Perugia Italy (IT) Lithuanian University of Health Sciences / Lietuvos sveikatos mokslų universitetas (LSMU) Lithuania (LT) University Medical Center Groningen (UMCG) / Universitair Medisch Centrum Groningen Netherlands (NL) Hospital Network Antwerp / Ziekenhuis Netwerk Antwerpen (ZNA) Belgium (BE) Universitätsklinikum Carl Gustav Carus Dresden Germany (DE) Hospital Universitario Insular de Gran Canaria Spain (ES) Katholisches Klinikum Bochum (St. Josef- und St. Elisabeth-Hospital gGmbH) Germany (DE) Ospedale Policlinico San Martino Italy (IT) Universitat Pompeu Fabra (UPF) Spain (ES) Centro Hospitalar e Universitário de Coimbra (CHUC) Portugal (PT)

How to cite

APA:

Uter, W., Wilkinson, S.M., Bauer, A., Borrego, L., Brans, R., Buhl, T.,... Pérez, R.G. (2026). Patch Test Results With Additions to the European Baseline Series, 2021/22—Joint European Results of the ESSCAA and the EBSB Working Groups of the ESCD, and the GEIDACC. Contact Dermatitis. https://doi.org/10.1111/cod.70183

MLA:

Uter, Wolfgang, et al. "Patch Test Results With Additions to the European Baseline Series, 2021/22—Joint European Results of the ESSCAA and the EBSB Working Groups of the ESCD, and the GEIDACC." Contact Dermatitis (2026).

BibTeX: Download